Having trouble accessing articles? Reset your cache.

Dacogen decitabine regulatory update

Germany's Federal Joint Committee (G-BA) said in a final benefit assessment that Orphan drug Dacogen decitabine from Johnson & Jonson has a "marginal" additional

Read the full 246 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE